BCL2 and prostate cancer: MiR-16 is often down-regulated in chronic lymphocytic leukaemia [72], gastric [73], ovarian [74] and prostate cancers as a tumor suppressor that targets and down-regulates the anti-apoptotic gene BCL2 [45].